Health-related heterogeneity in brain aging and associations with longitudinal change in cognitive function

Decomposing the effect of normal aging and Alzheimer's disease in brain morphological changes via learned aging templates

Alzheimer's disease (AD) subjects usually show more profound morphological changes with time compared to cognitively normal (CN) individuals. These changes are the combination of two major biological processes: normal aging and AD pathology. Investigating normal aging and residual morphological changes separately can increase our understanding of the disease. This paper proposes two scores, the aging score (AS) and the AD-specific score (ADS), whose purpose is to measure these two components of brain atrophy independently. For this, in the first step, we estimate the atrophy due to the normal aging of CN subjects by computing the expected deformation required to match imaging templates generated at different ages. We used a state-of-the-art generative deep learning model for generating such imaging templates. In the second step, we apply deep learning-based diffeomorphic registration to align the given image of a subject with a reference imaging template. Parametrization of this deformation field is then decomposed voxel-wise into their parallel and perpendicular components with respect to the parametrization of the expected atrophy of CN individuals in one year computed in the first step. AS and ADS are the normalized scores of these two components, respectively. We evaluated these two scores on the OASIS-3 dataset with 1,014 T1-weighted MRI scans. Of these, 326 scans were from CN subjects, and 688 scans were from subjects diagnosed with AD at various stages of clinical severity, as defined by clinical dementia rating (CDR) scores. Our results reveal that AD is marked by both disease-specific brain changes and an accelerated aging process. Such changes affect brain regions differently. Moreover, the proposed scores were sensitive to detect changes in the early stages of the disease, which is promising for its potential future use in clinical studies. Our code is freely available at https://github.com/Fjr9516/DBM_with_DL .

Safety of solid oncology drugs in older patients: a narrative review

The older population represents ∼50%-60% of the population of newly diagnosed patients with cancer. Due to physiological and pathological aging and the increased presence of comorbidities and frailty factors, this population is at higher risk of serious toxicity from anticancer drugs and, consequently, often under-treated. Despite the complexity of these treatments, a good knowledge of the pharmacology of anticancer drugs and potentially risky situations can limit the emergence of potentially lethal toxicities in this population. This review focuses on optimizing systemic oncology treatments for older patients, emphasizing the unique characteristics of each therapeutic class and the necessity for a precautionary approach for this vulnerable population.

Elucidating Multimodal Imaging Patterns in Accelerated Brain Aging: Heterogeneity through a Discriminant Analysis Approach Using the UK Biobank Dataset

Accelerated brain aging (ABA) intricately links with age-associated neurodegenerative and neuropsychiatric diseases, emphasizing the critical need for a nuanced exploration of heterogeneous ABA patterns. This investigation leveraged data from the UK Biobank (UKB) for a comprehensive analysis, utilizing structural magnetic resonance imaging (sMRI), diffusion magnetic resonance imaging (dMRI), and resting-state functional magnetic resonance imaging (rsfMRI) from 31,621 participants. Pre-processing employed tools from the FMRIB Software Library (FSL, version 5.0.10), FreeSurfer, DTIFIT, and MELODIC, seamlessly integrated into the UKB imaging processing pipeline. The Lasso algorithm was employed for brain-age prediction, utilizing derived phenotypes obtained from brain imaging data. Subpopulations of accelerated brain aging (ABA) and resilient brain aging (RBA) were delineated based on the error between actual age and predicted brain age. The ABA subgroup comprised 1949 subjects (experimental group), while the RBA subgroup comprised 3203 subjects (control group). Semi-supervised heterogeneity through discriminant analysis (HYDRA) refined and characterized the ABA subgroups based on distinctive neuroimaging features. HYDRA systematically stratified ABA subjects into three subtypes: SubGroup 2 exhibited extensive gray-matter atrophy, distinctive white-matter patterns, and unique connectivity features, displaying lower cognitive performance; SubGroup 3 demonstrated minimal atrophy, superior cognitive performance, and higher physical activity; and SubGroup 1 occupied an intermediate position. This investigation underscores pronounced structural and functional heterogeneity in ABA, revealing three subtypes and paving the way for personalized neuroprotective treatments for age-related neurological, neuropsychiatric, and neurodegenerative diseases.

Rethinking Dementia Risk Prediction: A Critical Evaluation of a Multimodal Machine Learning Predictive Model

A recent study by Ding et al. explores the integration of artificial intelligence (AI) in predicting dementia risk over a 10-year period using a multimodal approach. While revealing the potential of machine learning models in identifying high-risk individuals through neuropsychological testing, MRI imaging, and clinical risk factors, the imperative of dynamic frailty assessment emerges for accurate late-life dementia prediction. The commentary highlights challenges associated with AI models, including dimensionality and data standardization, emphasizing the critical need for a dynamic, comprehensive approach to reflect the evolving nature of dementia and improve predictive accuracy.